Niandi Tan

Niandi Tan

Auto-generated profile, based on publicly available information

Niandi Tan

Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
NTNiandi Tan
Niandi Tan
KGKok Ann Gwee
Kok Ann Gwee
JTJan Tack
Jan Tack
MZMengyu Zhang
Mengyu Zhang
YLYuwen Li
Yuwen Li
YXYinglian Xiao
Yinglian Xiao

12 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
QZQianjun Zhuang
Qianjun Zhuang
SCSongfeng Chen
Songfeng Chen
XZXuyu Zhou
Xuyu Zhou
XJXingyu Jia
Xingyu Jia
MZMengyu Zhang
Mengyu Zhang
YXYinglian Xiao
Yinglian Xiao
INTRODUCTION: Los Angeles grade C/D esophagitis is a severe manifestation of gastroesophageal reflux disease that require active treatment and close follow-up. Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials. Randomized controlled trials were eligible for inclusion if efficacy of P-CAB and PPI in healing grade C/D esophagitis was reported. Pooled risk ratios and risk difference with 95% credible intervals were used to summarize estimated effect of each comparison. The benefit of treatments was ranked using the surface under the cumulative probability ranking score. RESULTS: Of 5,876 articles identified in the database, 24 studies were eligible. Studies included incorporated 3 P-CAB (vonoprazan, tegoprazan, and keverprazan) and 6 PPI (lansoprazole, esomeprazole, omeprazole, rabeprazole extended-release (ER), pantoprazole, and dexlansoprazole). Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked the first among PPI in initial and maintained healing of grade C/D esophagitis (surface under the cumulative probability ranking score = 0.89 and 0.87, respectively). Vonoprazan had similar risk of incurring adverse events, severe adverse events, and withdrawal to drug when compared with PPI. For those who attempted lower maintenance treatment dose, 10 mg of vonoprazan q.d. was a reasonable choice, considering its moderate efficacy and safety. DISCUSSION: Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPI, with moderate short-term and long-term safety.

21 February 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SQSabrina Xin Zi Quek
Sabrina Xin Zi Quek
ELEvelyn Xiu Ling Loo
Evelyn Xiu Ling Loo
ADAlla Demutska
Alla Demutska
CCChun En Chua
Chun En Chua
GKGuan Sen Kew
Guan Sen Kew
KSKewin Tien Ho Siah
Kewin Tien Ho Siah
Background and Aim: Gastrointestinal manifestations of the coronavirus disease 2019 (COVID‐19) pandemic may mimic irritable bowel syndrome (IBS), and social distancing measures may affect IBS patients negatively. We aimed to study the impact of COVID‐19 on respondents with self‐reported IBS.Methods: We conducted an anonymized survey from May to June 2020 in 33 countries. Knowledge, attitudes, and practices on personal hygiene and social distancing as well as psychological impact of COVID‐19 were assessed. Statistical analysis was performed to determine differences in well‐being and compliance to social distancing measures between respondents with and without self‐reported IBS. Factors associated with improvement or worsening of IBS symptoms were evaluated.Results: Out of 2704 respondents, 2024 (74.9%) did not have IBS, 305 (11.3%) had self‐reported IBS, and 374 (13.8%) did not know what IBS was. Self‐reported IBS respondents reported significantly worse emotional, social, and psychological well‐being compared with non‐IBS respondents and were less compliant to social distancing measures (28.2% vs 35.3%, P = 0.029); 61.6% reported no change, 26.6% reported improvement, and 11.8% reported worsening IBS symptoms. Higher proportion of respondents with no change in IBS symptoms were willing to practice social distancing indefinitely versus those who deteriorated (74.9% vs 51.4%, P = 0.016). In multivariate analysis, willingness to continue social distancing for another 2–3 weeks (vs longer period) was significantly associated with higher odds of worsening IBS.Conclusion: Our study showed that self‐reported IBS respondents had worse well‐being and compliance to social distancing measures than non‐IBS respondents. Future research will focus on occupational stress and dietary changes during COVID‐19 that may influence IBS.

30 April 2023 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
XJXingyu Jia
Xingyu Jia
SCSongfeng Chen
Songfeng Chen
QZQianjun Zhuang
Qianjun Zhuang
NTNiandi Tan
Niandi Tan
MZMengyu Zhang
Mengyu Zhang
YXYinglian Xiao
Yinglian Xiao
Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, and Yinglian Xiao*. J Neurogastroenterol Motil 2023;29:145-55. https://doi.org/10.5056/jnm22176

13 August 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
MZMengyu Zhang
Mengyu Zhang
NTNiandi Tan
Niandi Tan
YLYuwen Li
Yuwen Li
MCMinhu Chen
Minhu Chen
YXYinglian Xiao
Yinglian Xiao

30 January 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SCSongfeng Chen
Songfeng Chen
MLMengya Liang
Mengya Liang
MZMengyu Zhang
Mengyu Zhang
NTNiandi Tan
Niandi Tan
YLYuqing Lin
Yuqing Lin
YXYinglian Xiao
Yinglian Xiao